Thousands of people with MS to receive first NHS-funded treatment to improve walking

Thousands of people living with multiple sclerosis (MS) in England will be offered the first NHS-funded medicine specifically designed to improve walking difficulties caused by the condition.

From today, fampridine (also known as Fampyra) will be routinely available on the NHS for eligible adults with MS. The twice-daily tablet works by helping electrical signals travel more effectively along nerves damaged by the disease, improving muscle function and mobility for some patients.

NHS England estimates that around 5,000 people will be eligible to receive the treatment during the first year. Patients will initially take the medicine for two to four weeks before their walking ability is reassessed. Those who experience a clear improvement will continue treatment, with regular clinical reviews.

Clinical trials found that fampridine improved walking speed in 43% of patients, helping many people walk further and more confidently. It is the first medicine licensed specifically to improve walking in adults with multiple sclerosis.

Multiple sclerosis is a lifelong condition affecting the brain and spinal cord that can cause problems with movement, balance and coordination. Until now, people experiencing walking difficulties have typically relied on physiotherapy, walking aids and supportive devices rather than a medicine specifically targeting mobility.

Stay informed with the stories shaping health and social care.

Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.